From J.P. Morgan: More Capital Will Boost Biopharma M&A in 2018

President Donald Trump’s tax overhaul, growing competition among drug developers, and new sources of capital will drive this year's merger-and-acquisition (M&A) activity well past the $200 billion annual volume of deals seen last year, EY has concluded in a report released today.EY's  2018 M&A Outlook and Firepower Report: Life Sciences Deals and Data  found that the tax overhaul—especially its one-time tax cut for U.S. companies that shift or "repatriate" prof